Tumor Progression and Metastasis

Tumor Progression - Cancer's Creepy Crawl

• Definition: Stepwise accumulation of (epi)genetic changes; results in ↑malignancy & ↑heterogeneity.
• Clonal Evolution: Darwinian selection of "fittest" subclones with growth/survival advantages.
  • Initial tumor often monoclonal; genetic instability fuels diversification.
• Tumor Heterogeneity: Diverse cell populations within a single tumor.
  • Implications: varied metastatic potential, drug resistance, treatment failure.
• Key Processes Acquired:
  • Sustained angiogenesis (e.g., VEGF).
  • Local invasion (e.g., MMPs).
  • Metastasis.

⭐ Tumor progression is not always linear; some tumors may acquire metastatic ability early, even before significant local growth (e.g., "born to be bad" phenotype).

Local Invasion - Breaking Down Walls

Tumors breach basement membranes and invade surrounding stroma, a critical step before metastasis. Key mechanisms include:

• Detachment ("Loosening of cells"):
  • ↓ E-cadherin expression (loss of cell-cell adhesion).
  • Cadherin switching (e.g., N-cadherin ↑).
• Degradation of Extracellular Matrix (ECM):
  • Secretion of proteolytic enzymes:
    • Matrix Metalloproteinases (MMPs) e.g., MMP-2, MMP-9.
    • Cathepsin D.
  • Loss of basement membrane integrity.
• Attachment to ECM Components:
  • Changes in integrin expression (e.g., αvβ3 integrin ↑).
  • Binding to fibronectin, laminin.
• Migration & Locomotion:
  • Propulsion through degraded matrix.
  • Stimulated by autocrine motility factors & ECM cleavage products.

📌 Mnemonic: Dogs Dig Awful Messes (Detachment, Degradation, Attachment, Migration)

⭐ Downregulation of E-cadherin is a key event in promoting local invasion and is often associated with epithelial-mesenchymal transition (EMT).

Metastatic Cascade - The Great Journey

• Highly complex, multi-step, and notably inefficient process where cancer cells disseminate from the primary tumor to establish secondary tumors at distant sites.
• Key Stages:
  • Liberation & Local Invasion: ↓E-cadherin (cell adhesion loss). ECM degradation by MMPs, cathepsins. Detachment.
  • Intravasation: Penetration into lymphatic/blood vessels.
  • Survival in Circulation: Evade immune attack (e.g., platelet shield), resist anoikis, form tumor emboli.
  • Extravasation & Homing: Adhere to endothelium, exit vessel. Organ-specific tropism (e.g., prostate cancer to bone).
  • Colonization & Angiogenesis: Micrometastasis forms. VEGF is crucial, driving angiogenesis for macrometastasis growth.

⭐ Paget's "Seed and Soil" hypothesis (1889) explains organotropism: "seeds" (tumor cells) colonize compatible "soil" (organ microenvironments).

Organ Tropism & Impact - Finding a Niche

• Organ Tropism: Metastases favor specific organs; "Seed and Soil" hypothesis (Paget).
• Mechanisms:
  • Anatomical routes: Blood/lymph flow (e.g., portal vein → liver).
  • Molecular matchmaking:
    • Chemokine axes: e.g., CXCR4-CXCL12.
    • Adhesion molecules: Tumor-endothelial interactions.
  • Supportive microenvironment ("soil"): Growth factors, ECM.
• Common Patterns:
  • Prostate → Bone (osteoblastic).
  • Breast, Lung, Kidney, Thyroid → Bone (often osteolytic/mixed).
  • 📌 Bone mets: PB KTL (Prostate, Breast, Kidney, Thyroid, Lung).
  • Colon, Stomach, Pancreas → Liver.
  • Lung, Breast → Brain, Adrenals.

  ⭐ Regional lymph nodes are the most common metastatic site; distant spread dictates prognosis.

• Clinical Impact:
  • Determines prognosis & treatment.
  • Metastasis is the primary cause of cancer death.

High‑Yield Points - ⚡ Biggest Takeaways

• Tumor progression: driven by genetic instability and clonal selection.
• Metastasis: spread to distant sites, the hallmark of malignancy.
• Metastatic cascade: invasion (ECM degradation), intravasation, circulation, extravasation, colonization.
• EMT (↓E-cadherin) is crucial for invasion and metastasis.
• Angiogenesis is essential for tumor growth >1-2 mm and metastasis.
• Common sites: lymph nodes (carcinomas), liver, lungs, bone.
• "Seed and soil" hypothesis explains organ-specific metastasis.